Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-06-24
2008-11-11
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S236800, C514S237800, C544S236000, C544S237000
Reexamination Certificate
active
07449464
ABSTRACT:
Compounds of the formula (I):wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRXor CRXRY; if X=NRXthen n is 1 or 2 and if X=CRXRYthen n is 1; RXis selected from the group consisting of H, optionally substituted C1-20alkyl, C5-20aryl, C3-20heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RYis selected from H, hydroxy, amino; or RXand RYmay together form a spiro-C3-7cycloalkyl or heterocyclyl group; RC1and RC2are both hydrogen, or when X is CRXRY, RC1, RC2, RXand RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1is selected from H and halo.
REFERENCES:
patent: 3813384 (1974-05-01), Vogelsang et al.
patent: 4665181 (1987-05-01), Thomas et al.
patent: 4841047 (1989-06-01), Engel et al.
patent: 5032617 (1991-07-01), Lee et al.
patent: 5041653 (1991-08-01), Lee et al.
patent: 5215738 (1993-06-01), Lee et al.
patent: 5556856 (1996-09-01), Engel et al.
patent: 5587384 (1996-12-01), Zhang et al.
patent: 5648355 (1997-07-01), Theoharides
patent: 5874444 (1999-02-01), West
patent: 5886178 (1999-03-01), Allen et al.
patent: 6197785 (2001-03-01), Jackson et al.
patent: 6340684 (2002-01-01), Napoletano et al.
patent: 6426415 (2002-07-01), Jackson et al.
patent: 6476048 (2002-11-01), Szabo et al.
patent: 6498160 (2002-12-01), Napoletano et al.
patent: 6514983 (2003-02-01), Li
patent: 6514984 (2003-02-01), Watanabe
patent: 6635642 (2003-10-01), Jackson et al.
patent: 6677333 (2004-01-01), Seko et al.
patent: 2002/0183325 (2002-12-01), Martin et al.
patent: 2004/0023968 (2004-02-01), Martin et al.
patent: 2005/0059663 (2005-03-01), Martin et al.
patent: 2005/0080096 (2005-04-01), Ishida et al.
patent: 2005/0227919 (2005-10-01), Kudos
patent: 2143745 (1973-03-01), None
patent: 3813531 (1988-04-01), None
patent: 287 032 (1991-02-01), None
patent: 0030861 (1981-06-01), None
patent: 0269968 (1988-06-01), None
patent: 0 355 750 (1990-02-01), None
patent: 0389995 (1990-10-01), None
patent: 0502575 (1992-09-01), None
patent: 0 590 551 (1994-04-01), None
patent: 0634404 (1995-01-01), None
patent: 699754 (1996-06-01), None
patent: 705903 (1996-10-01), None
patent: 0 792 643 (1997-09-01), None
patent: 2 262 513 (1975-09-01), None
patent: 721286 (1955-01-01), None
patent: 2 384 776 (2004-03-01), None
patent: MI98A001671 (1999-04-01), None
patent: 54156526 (1979-12-01), None
patent: 58164577 (1983-09-01), None
patent: 62-252774 (1987-11-01), None
patent: WO 91/18591 (1991-12-01), None
patent: WO 93/14086 (1993-07-01), None
patent: WO 94/10151 (1994-05-01), None
patent: WO 95/24379 (1995-09-01), None
patent: WO 96/19225 (1996-06-01), None
patent: WO 98/43477 (1998-10-01), None
patent: WO 98/51308 (1998-11-01), None
patent: WO 99/08680 (1999-02-01), None
patent: WO 99/11624 (1999-03-01), None
patent: WO 99/11645 (1999-03-01), None
patent: WO 99/11649 (1999-03-01), None
patent: WO 99/44612 (1999-09-01), None
patent: WO 99/47494 (1999-09-01), None
patent: WO 00/05219 (2000-02-01), None
patent: WO 00/42040 (2000-07-01), None
patent: WO 00/44726 (2000-08-01), None
patent: WO 00/67734 (2000-11-01), None
patent: WO 01/12199 (2001-02-01), None
patent: WO 01/16136 (2001-03-01), None
patent: WO 01/16137 (2001-03-01), None
patent: WO 01/21615 (2001-03-01), None
patent: WO 01/23390 (2001-04-01), None
patent: WO 01/57038 (2001-08-01), None
patent: WO 01/79184 (2001-10-01), None
patent: WO 01/85686 (2001-11-01), None
patent: WO 01/85687 (2001-11-01), None
patent: WO 01/87845 (2001-11-01), None
patent: WO 01/90077 (2001-11-01), None
patent: WO 02/36576 (2002-05-01), None
patent: WO 03/070726 (2002-05-01), None
patent: WO 02/44157 (2002-06-01), None
patent: WO 02/068407 (2002-09-01), None
patent: WO 02/090334 (2002-11-01), None
patent: WO 02/094790 (2002-11-01), None
patent: WO 03/007959 (2003-01-01), None
patent: WO 03/051879 (2003-06-01), None
patent: WO 03/055865 (2003-07-01), None
patent: WO 03/057145 (2003-07-01), None
patent: WO 03/063874 (2003-08-01), None
patent: WO 03/070707 (2003-08-01), None
patent: WO 03/080581 (2003-10-01), None
patent: WO 03/093261 (2003-11-01), None
patent: WO 2004/080976 (2004-09-01), None
patent: WO 2005/053662 (2005-06-01), None
Vippagunta et al., “Crystalline solids”, Advanced Drug Delivery Reviews 48 (2001)3-26.
U.S. Appl. No. 11/873,671, filed Oct. 17, 2007, entitled “Phthalazinone Derivative.”
“Applied Biosystems 430A Users Manual”, ABI Inc., Foster City, California (book not provided).
“Current Protocols in Molecular Biology”, 1992, Eds. AUSUBEL et al., John Wiley & Sons (book not provided).
“From DNA damage and stress signalling to cell death”, 2000, Eds. De Murcia, G and Shall, S, Oxford University Press (book not provided).
“Handbook of Pharmaceutical Additives”, 2001, 2 Ed., Synapse Information Resources Inc., Endicott, New York, USA (book not provided).
“Handbook of Pharmaceutical Excipients”, 1994, 2 Ed. (book not provided).
“Molecular Cloning: A Laboratory Manual”, 2001, 3 Ed., Sambrook & Russell, Cold Spring Harbor Laboratory Press, New York (book not provided).
“PCR Protocols; A Guide to Methods and Application”, 1990, Eds. Innis et al., Academic Press, New York (book not provided).
“PCR Technology”, 1989, Eds. EHRLICH, Stockholm Press, New York (book not provided).
“Remington's Pharmaceutical Sciences”, 2000, 20 Ed., Lippincott, Williams & Wilkins (book not provided).
Affar, E. B., et al.,Anal. Biochem., 1998, vol. 259, No. 2, pp. 280-283.
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology, Supplement. Archiv fur Toxikologie. Supplement, vol. 7, pp. 219-231 (1984).
Althaus, F.R. and Richter, C., 1987, ADP-Ribosylation of Proteins: Enzymology and Biological Significance, Springer-Verlag, Berlin (book not provided).
Ame, et al.,J. Biol. Chem., 1999, vol. 274, p. 17860-17868.
Angell, et al.,EMBO J., 1997, vol. 16, No. 12, pp. 3675-3684.
Arnaudeau, C., et al.,J. Mol. Biol, 2001, vol. 307, pp. 1235-1245.
Banasik, M., et al., “Specific Inhibitors of Poly (ADP-Ribose) Synthetase and Mono (ADP-ribosyl) transferse”,J. Biol. Chem., 1992, vol. 267, pp. 1569-1575.
Banasik, M., et al.,Mol. Cell Biochem., 1994, vol. 138, pp. 185-197.
Ben-Hur et al., 1984,British Journal of Cancer, 49 (Suppl. VI): 39-42.
Berge et al., 1977, “Pharmaceutically Acceptable Salts,”J. Pharm. Sci., vol. 66, pp. 1-19.Protective Groups in Organic Synthesis(T. Green and P. Wuts, Wiley, 1991).
Berger, N. A., et al., “Poly (ADP-ribose) in cellular response to DNA damage”,Radiation Research, 1985, vol. 101, pp. 4-14.
Bhattacharyya, A., et al.,J. Biol. Chem., 2000, vol. 275, pp. 23899-23903.
Bodanzsky, M., Bodanzsky, A., “The Practice of Peptide Synthesis”, 1984, Springer Verlag, New York (book not provided).
Bold et. al., J. Med. Chem., 2000, 43, 3200.
Bold, G., et al., “New anilinophthalazines as potent and orally well absorbed inhibitors of the FEBF receptor tyrosine kinases useful as antagonists of tumour-driven angiogenesis”,J. Med. Chem., 2000, vol. 43, No. 12, pp. 2310-2323.
Bowman et al., “Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU 1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro ”Britishi Journal of Cancer, vol. 84(1), pp. 106-112 (2001).
Brummelkamp, T. R., et al.,Science, 2002, vol. 296, pp. 550-553.
Bundgaard, Hans, Design of Prodrugs, p. 1 © 1985 Elsevier Science Publishers.
Burzio, L., et al., “Poly (adenosine diphosphoribose) synthase activity of isolated nuclei of normal and leukemic leukocytes (38930)”,Proc. Soc. Exp. Bio. Med., 1975, vol. 149, pp. 933-938.
Cantoni, O., et al., “Hydrogen peroxide insult in cultured mammalian cells: relationships between DNA single-strand breakage, poly (ADP-ribose) metabolism and cell killing”,Biochim. Bio
Ashworth Alan
Barr Martin Niall Morrison
Cockcroft Xiao-Ling Fan
Jackson Stephen Philip
Kerrigan Frank
Finnegan Henderson Farabow Garrett & Dunner LLP
Kudos Pharmaceuticals Limited
Maybridge Limited
Ward Paul V.
Wilson James O.
LandOfFree
Phthalazinone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phthalazinone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phthalazinone derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4049511